HTG Molecular Diagnostics Management

Management criteria checks 3/4

HTG Molecular Diagnostics' CEO is John Lubniewski, appointed in Apr 2018, has a tenure of 4.92 years. total yearly compensation is $736.74K, comprised of 62.4% salary and 37.6% bonuses, including company stock and options. directly owns 0.053% of the company’s shares, worth €3.12K. The average tenure of the management team and the board of directors is 5.2 years and 4.3 years respectively.

Key information

John Lubniewski

Chief executive officer

US$736.7k

Total compensation

CEO salary percentage	62.4%
CEO tenure	4.9yrs
CEO ownership	0.05%
Management average tenure	5.2yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Lubniewski's remuneration changed compared to HTG Molecular Diagnostics's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	-US$22m
Jun 30 2022	n/a	n/a	-US$22m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$737k	US$460k	-US$17m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$1m	US$416k	-US$21m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$1m	US$384k	-US$19m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$1m	US$327k	-US$16m
Sep 30 2018	n/a	n/a	-US$16m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$19m
Dec 31 2017	US$691k	US$307k	-US$19m
Sep 30 2017	n/a	n/a	-US$23m
Jun 30 2017	n/a	n/a	-US$24m
Mar 31 2017	n/a	n/a	-US$25m
Dec 31 2016	US$432k	US$300k	-US$26m

Compensation vs Market: John's total compensation ($USD736.74K) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Lubniewski (58 yo)

4.9yrs

Tenure

US$736,741

Compensation

Mr. John L. Lubniewski serves as President of HTG Molecular Diagnostics, Inc. since April 16, 2018 and also serves as its Chief Executive Officer since April 2019. Mr. Lubniewski served as Chief Operating...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Lubniewski	President	4.9yrs	US$736.74k	0.053% $ 3.1k
Shaun McMeans	Senior VP	11.1yrs	US$510.60k	0.040% $ 2.3k
Byron Lawson	Senior VP & Chief Commercial Officer	5.2yrs	US$440.30k	0.023% $ 1.3k
Laura Godlewski	Senior Vice President of Finance & Administration	1.2yrs	no data	0.018% $ 1.1k
Debra Gordon	Senior VP & Chief Legal Counsel	11.8yrs	US$296.70k	no data
Patrick Roche	Senior Vice President of Research & Development	8.9yrs	US$507.38k	no data
Stephen Barat	Senior Vice President of Therapeutics	1.4yrs	no data	0.062% $ 3.6k
Christina Carruthers	Vice President of Target Strategy & Early Development	no data	no data	no data
Debrah Thompson	Vice President of Scientific Innovation	no data	no data	no data

5.2yrs

Average Tenure

59yo

Average Age

Experienced Management: 65H's management team is seasoned and experienced (5.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
John Lubniewski	President	3.9yrs	US$736.74k	0.053% $ 3.1k
Michelle Griffin	Independent Director	4.6yrs	US$81.00k	0.00063% $ 36.8
Lee McCracken	Independent Director	7.4yrs	US$71.00k	0.0013% $ 74.3
Ann Hanham	Independent Chairman of the Board	6.6yrs	US$100.00k	0.0019% $ 108.2
Donnie Hardison	Independent Director	6.8yrs	US$72.00k	0.0031% $ 182.4
Thomas Dubensky	Director	less than a year	no data	no data
Christopher Kiritsy	Non-Employee Independent Director	1.2yrs	no data	no data
Davide Ruggero	Member of Scientific Advisory Board	no data	no data	no data
Frank Slack	Member of Scientific Advisory Board	no data	no data	no data
Robert Spitale	Member of Therapeutics Scientific Advisory Board	1.1yrs	no data	no data
Amir Horowitz	Member of Scientific Advisory Board	no data	no data	no data
Mateusz Koptyra	Member of Scientific Advisory Board	no data	no data	no data

4.3yrs

Average Tenure

64yo

Average Age

Experienced Board: 65H's board of directors are considered experienced (4.3 years average tenure).

HTG Molecular Diagnostics Management

Management criteria checks 3/4

Key information

Recent management updates

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Announces Board Changes

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Announces Resignation of Timothy B. Johnson as Executive Chairman and a Member of the Board of Directors

Recent updates

Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index

HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Filed for Bankruptcy

HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq

HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization

HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022

HTG Molecular Diagnostics, Inc. has completed a Follow-on Equity Offering.

HTG Molecular Diagnostics, Inc. Receives Non-Compliance Notice From Nasdaq

Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.60 loss in 3Q 2021)

HTG Molecular Diagnostics, Inc. announced that it has received $0.0001 million in funding

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

HTG Molecular Diagnostics, Inc. Announces Board Changes

Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.39 loss in 2Q 2021)

HTG Molecular Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Releases Second Whitepaper for Its Transcriptome-Informed Approach to Drug Discovery

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.81 loss per share (vs US$0.80 loss in 1Q 2021)

HTG Molecular Diagnostics, Inc. to Report Q1, 2022 Results on May 12, 2022

HTG Molecular Diagnostics, Inc. Expands Features of Proprietary HTG EdgeSeq Technology

Full year 2021 earnings released: US$2.47 loss per share (vs US$4.51 loss in FY 2020)

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2021

HTG Molecular Diagnostics, Inc. Completes HTP Product Next-Phase Development Milestone

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$1.12 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$1.30 loss in 2Q 2020)

HTG Molecular Diagnostics, Inc. Announces Commercial Launch and Immediate Availability of its HTG Transcriptome Panel

HTG Molecular Diagnostics, Inc. Announces Completion of Product Design Lock for the HTG Transcriptome Panel

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.27 loss in 1Q 2020)

HTG Molecular Diagnostics, Inc. Reports Preliminary Financial Results for the First Quarter Ended March 31, 2021 and Full Year 2021

Full year 2020 earnings released: US$4.51 loss per share (vs US$7.60 loss in FY 2019)

HTG Molecular Diagnostics, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021

HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology

New 90-day high: €6.55

New 90-day high: €6.25

HTG Molecular Diagnostics, Inc. Announces Resignation of Timothy B. Johnson as Executive Chairman and a Member of the Board of Directors

New 90-day high: €5.11

New 90-day low: €0.23

Revenue misses expectations

Third quarter 2020 earnings released: US$0.075 loss per share

HTG Molecular Diagnostics, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: €0.24

New 90-day low - €0.29

New 90-day low - €0.37

First half earnings released

HTG Molecular Diagnostics, Inc. to Report Q2, 2020 Results on Aug 11, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age